AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9726554 — intervention group
Group type: EXPERIMENTAL
Intervention: Examinations by hand surgeons and hand therapists
Number of subjects: 12
Study 7831412 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical Time Intervention
Number of subjects: 0
Study 7831412 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 0
Study 3207560 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg single dose) with indomethacin pretreatment (25 mg four times daily for 3 days)
Number of subjects: 12
Study 3207560 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin treatment alone
Number of subjects: 12
Study 3207560 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine and felodipine plus indomethacin
Number of subjects: 12
Study 3207560 — intervention group
Group type: COMPARATOR
Intervention: Felodipine (10 mg single dose)
Number of subjects: 12
Study 30827852 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy extracorporeal shockwave therapy (0.05-0.20mJ/mm2, frequency of 4Hz, 1000 to 2000 shocks, once per week for 4 weeks)
Number of subjects: 45
Study 30827852 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (ESWT without energy)
Number of subjects: 45
Study 27884801 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible duty hour policies
Number of subjects: 154
Study 27884801 — intervention group
Group type: COMPARATOR
Intervention: Standard duty hour policies
Number of subjects: 154
Study 25811486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management (home visits and telephone calls for three years)
Number of subjects: 340
Study 25811486 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 340
Study 25811486 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based case management
Number of subjects: 340
Study 24004232 — intervention group
Group type: COMPARATOR
Intervention: Butorphanol (0.4 mg/kg, SC)
Number of subjects: 22
Study 24004232 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.6 mg/kg, SC)
Number of subjects: 22
Study 21385426 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education during the first trimester of gestation on healthy hygiene-dietetic habits and the importance of an adequate iodine nutritional status
Number of subjects: 898
Study 19397429 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.25% bupivacaine infiltration
Number of subjects: 40
Study 19397429 — intervention group
Group type: COMPARATOR
Intervention: No infiltration (control group)
Number of subjects: 40
Study 17239710 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior fat pad (AFP) maintenance
Number of subjects: 180
Study 17239710 — intervention group
Group type: COMPARATOR
Intervention: AFP removal
Number of subjects: 180
Study 17239710 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP maintenance
Number of subjects: 180
Study 15129200 — intervention group
Group type: EXPERIMENTAL
Intervention: Mulligan's Mobilization With Movement (MWM)
Number of subjects: 18
Study 15129200 — intervention group
Group type: COMPARATOR
Intervention: Naloxone
Number of subjects: 18
Study 15129200 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 18
Study 15129200 — intervention group
Group type: COMPARATOR
Intervention: No-substance control
Number of subjects: 18
Study 11968135 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance microscopy imaging at 11.7 T
Number of subjects: 4
Study 11968135 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological slices
Number of subjects: 4
Study 10199880 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal butorphanol
Number of subjects: 47
Study 10199880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 8564589 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videotapes mailed to study group
Number of subjects: 4246
Study 8564589 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational materials)
Number of subjects: 4246
Study 8564589 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey respondents from study group
Number of subjects: 4246
Study 1972861 — intervention group
Group type: EXPERIMENTAL
Intervention: xamoterol, 200 mg twice a day
Number of subjects: 51
Study 1972861 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study 93486 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual speech therapy
Number of subjects: 13
Study 93486 — intervention group
Group type: COMPARATOR
Intervention: Intervention from untrained volunteers
Number of subjects: 13
Study 31790913 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT)
Number of subjects: 199
Study 31790913 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 199
Study 31045830 — intervention group
Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT) administered 3 times a day for 4 weeks
Number of subjects: 60
Study 31045830 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 3 times a day for 4 weeks
Number of subjects: 60
Study 31045830 — intervention group
Group type: EXPERIMENTAL
Intervention: Soshiho-tang (SSHT)
Number of subjects: 60
Study 31045830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28671102 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline intervention
Number of subjects: 0
Study 28671102 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalping forehead flap technique
Number of subjects: 0
Study 26027102 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ionophore A23187-activation
Number of subjects: 2
Study 26027102 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 2
Study 22928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type-A (BoNT-A) injection
Number of subjects: 15
Study 22928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (10 weeks)
Number of subjects: 15
Study 22928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training and BoNT-A (combined intervention)
Number of subjects: 15
Study 22928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal Attainment Scale (GAS) assessment
Number of subjects: 15
Study 22928803 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Number of subjects: 15
Study 22928803 — intervention group
Group type: COMPARATOR
Intervention: Control period (no intervention)
Number of subjects: 15
Study 21342644 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed concurrent chemoradiotherapy (Paclitaxel liposme 135 mg/m²-175 mg/m², d1 and cisplatin 70 mg/m²-80 mg/m², d2, 3 weeks repeat)
Number of subjects: 60
Study 21342644 — intervention group
Group type: COMPARATOR
Intervention: Sequential radiotherapy (4-6 cycles of chemotherapy followed by one cycle of radiotherapy)
Number of subjects: 60
Study 21342644 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy followed concurrent chemoradiotherapy
Number of subjects: 60
Study 21342644 — intervention group
Group type: COMPARATOR
Intervention: Sequential radiotherapy
Number of subjects: 60
Study 19688338 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg once daily (n = 230)
Number of subjects: 581
Study 19688338 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (n = 232)
Number of subjects: 581
Study 19688338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 114)
Number of subjects: 581
Study 17763372 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Number of subjects: 3049
Study 17763372 — intervention group
Group type: EXPERIMENTAL
Intervention: pamidronate
Number of subjects: 3049
Study 17763372 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3049
Study 15108949 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm massage by significant others
Number of subjects: 59
Study 15108949 — intervention group
Group type: COMPARATOR
Intervention: Control group (no arm massage)
Number of subjects: 59
Study 11211642 — intervention group
Group type: EXPERIMENTAL
Intervention: Televised antimarijuana campaigns (3 campaigns total; 2 in one county, 1 in comparison community)
Number of subjects: 100
Study 11211642 — intervention group
Group type: COMPARATOR
Intervention: Control community (1 campaign)
Number of subjects: 100
Study 9377538 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (300 mg)
Number of subjects: 0
Study 9377538 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (20 mg)
Number of subjects: 0
Study 9377538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8467105 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically increased vitamin intake for 8 weeks
Number of subjects: 498
Study 8467105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 498
Study 3516092 — intervention group
Group type: EXPERIMENTAL
Intervention: tibalosine 150 mg daily
Number of subjects: 26
Study 3516092 — intervention group
Group type: EXPERIMENTAL
Intervention: tibalosine plus atenolol 100 mg
Number of subjects: 26
Study 3516092 — intervention group
Group type: COMPARATOR
Intervention: tibalosine plus chlorthalidone 50 mg
Number of subjects: 26
Study 3516092 — intervention group
Group type: COMPARATOR
Intervention: tibalosine
Number of subjects: 26
Study 31502387 — intervention group
Group type: EXPERIMENTAL
Intervention: Horse riding simulator (HRS)
Number of subjects: 24
Study 31502387 — intervention group
Group type: COMPARATOR
Intervention: Corner seat placement (Control)
Number of subjects: 24
Study 31053348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime administered before skin incision
Number of subjects: 42
Study 31053348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime administered after cutting the umbilical cord
Number of subjects: 42
Study 31053348 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 42
Study 27890592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fabuless® emulsion (FEM)
Number of subjects: 18
Study 27890592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy emulsion with dairy emulsifier (DEDE)
Number of subjects: 18
Study 27890592 — intervention group
Group type: EXPERIMENTAL
Intervention: Dairy emulsion with soy lecithin emulsifier (DESE)
Number of subjects: 18
Study 27890592 — intervention group
Group type: COMPARATOR
Intervention: Dairy control (DCON)
Number of subjects: 18
Study 27890592 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmolein emulsion with dairy emulsifier (PEDE)
Number of subjects: 18
Study 27890592 — intervention group
Group type: COMPARATOR
Intervention: Palmolein control (PCON)
Number of subjects: 18
Study 25838311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (NaNO2) at 50 μg/kg/min
Number of subjects: 25
Study 25838311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (NaNO2) at 10 μg/kg/min
Number of subjects: 25
Study 23785676 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous specific immunotherapy in 57 allergic patients (70.3%)
Number of subjects: 124
Study 23785676 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal glucocorticosteroids in 47 patients with rhinitis medicamentosa (37.9%)
Number of subjects: 124
Study 23785676 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 124
Study 20979591 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d
Number of subjects: 30
Study 20979591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19126110 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing pressure of 0.15 N
Number of subjects: 17
Study 19126110 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing pressure of 0.25 N
Number of subjects: 17
Study 19126110 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing pressure (both 0.15 N and 0.25 N)
Number of subjects: 17
Study 17597387 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetics education module provided by Reach to Recovery peer volunteers
Number of subjects: 113
Study 17597387 — intervention group
Group type: COMPARATOR
Intervention: No genetics education module
Number of subjects: 113
Study 15536601 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide treatment
Number of subjects: 0
Study 15536601 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 15536601 — intervention group
Group type: COMPARATOR
Intervention: No pharmacologic treatment
Number of subjects: 0
Study 15536601 — intervention group
Group type: COMPARATOR
Intervention: General population comparisons (non-obese vs obese)
Number of subjects: 0
Study 11559654 — intervention group
Group type: EXPERIMENTAL
Intervention: olsalazine 2.0 g daily for 52 weeks
Number of subjects: 328
Study 11559654 — intervention group
Group type: COMPARATOR
Intervention: placebo for 52 weeks
Number of subjects: 328
Study 9211442 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment for 6 weeks
Number of subjects: 36
Study 9211442 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 36
Study 8290432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 12
Study 8290432 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 12
Study 3721903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleotide-supplemented milk formula
Number of subjects: 84
Study 3721903 — intervention group
Group type: COMPARATOR
Intervention: Milk formula
Number of subjects: 84
Study 3721903 — intervention group
Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 84
Study 2527533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril (0.5 to 5 mg dose range)
Number of subjects: 24
Study 31122027 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 176
Study 31122027 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical management
Number of subjects: 176
Study 30740640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 95
Study 30740640 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 95
Study 28619118 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 120
Study 28619118 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW-APN (high molecular weight adiponectin)
Number of subjects: 120
Study 24996117 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week home-based exercise programme
Number of subjects: 142
Study 24996117 — intervention group
Group type: COMPARATOR
Intervention: Practice as usual
Number of subjects: 142
Study 22484418 — intervention group
Group type: EXPERIMENTAL
Intervention: Extramedullary (EM) femoral alignment system
Number of subjects: 91
Study 22484418 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary (IM) femoral alignment system
Number of subjects: 91
Study 21344327 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotics (amoxicillin and metronidazole) in combination with non-surgical subgingival debridement
Number of subjects: 0
Study 21344327 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical subgingival debridement
Number of subjects: 0
Study 19298641 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. paricalcitol (0.04 ug/kg)
Number of subjects: 25
Study 19298641 — intervention group
Group type: COMPARATOR
Intervention: i.v. calcitriol (0.01 ug/kg)
Number of subjects: 25
Study 16403695 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-session cognitive behaviour therapy-based group intervention
Number of subjects: 33
Study 12808136 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1.5 milliunits/kg of fat‐free mass per min)
Number of subjects: 0
Study 12808136 — intervention group
Group type: COMPARATOR
Intervention: Insulin (low to high levels)
Number of subjects: 0
Study 10702462 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (50 microg/mL) by syringe from an infusion pump
Number of subjects: 40
Study 10702462 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil 20 microg/mL through a minidrip set
Number of subjects: 40
Study 9112968 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin type A (BtA)
Number of subjects: 14
Study 9112968 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 14
Study 7968331 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mL 2% lidocaine intrathecally (Group A)
Number of subjects: 12
Study 7968331 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mL 2% lidocaine epidurally (Group B)
Number of subjects: 12
Study 3707671 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (600 mg/day)
Number of subjects: 12
Study 3707671 — intervention group
Group type: EXPERIMENTAL
Intervention: diet plus bezafibrate
Number of subjects: 12
Study 3707671 — intervention group
Group type: COMPARATOR
Intervention: diet plus placebo
Number of subjects: 12
Study 29395407 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy session after wound care in addition to standard care
Number of subjects: 135
Study 29395407 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 135
Study 29395407 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy for children older than 5 years
Number of subjects: 135
Study 27484456 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS over the left inferior frontal gyrus (1 mA, 20 minutes)
Number of subjects: 58
Study 27484456 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS over the left inferior frontal gyrus
Number of subjects: 58
Study 23574660 — intervention group
Group type: EXPERIMENTAL
Intervention: GP plus workplace health advisers
Number of subjects: 60
Study 23574660 — intervention group
Group type: COMPARATOR
Intervention: GP alone
Number of subjects: 60
Study 23762840 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field radiotherapy (IFRT)
Number of subjects: 0
Study 23762840 — intervention group
Group type: COMPARATOR
Intervention: Elective nodal irradiation (ENI)
Number of subjects: 0
Study 21223769 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial stimulation
Number of subjects: 759
Study 21223769 — intervention group
Group type: COMPARATOR
Intervention: Control (no endometrial stimulation)
Number of subjects: 759
Study 17922535 — intervention group
Group type: EXPERIMENTAL
Intervention: Prodieting message
Number of subjects: 139
Study 17922535 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidieting message
Number of subjects: 139
Study 17922535 — intervention group
Group type: COMPARATOR
Intervention: Control message
Number of subjects: 139
Study 15917007 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Training Condition
Number of subjects: 15
Study 15917007 — intervention group
Group type: COMPARATOR
Intervention: Standard Training Condition
Number of subjects: 15
Study 12174057 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fluridil
Number of subjects: 43
Study 12174057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 12174057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluridil (former placebo subjects)
Number of subjects: 43
Study 9640121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 4 micrograms.ml‐1
Number of subjects: 40
Study 9640121 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol target concentration of 6 micrograms.ml‐1
Number of subjects: 40
Study 9640121 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide 67% in oxygen
Number of subjects: 40
Study 9640121 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 40
Study 9640121 — intervention group
Group type: COMPARATOR
Intervention: Technique using nitrous oxide supplemented with alfentanil
Number of subjects: 40
Study 7658266 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal prongs
Number of subjects: 118
Study 7658266 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal catheter
Number of subjects: 118
Study 2748931 — intervention group
Group type: EXPERIMENTAL
Intervention: High prescribed tempo
Number of subjects: 75
Study 2748931 — intervention group
Group type: EXPERIMENTAL
Intervention: Low prescribed tempo
Number of subjects: 75
Study 2748931 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred tempo
Number of subjects: 75
Study 2748931 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing tempo
Number of subjects: 75
Study 2748931 — intervention group
Group type: EXPERIMENTAL
Intervention: Discovery learning (no prescribed tempo)
Number of subjects: 75
Study 773736 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 23
Study 773736 — intervention group
Group type: COMPARATOR
Intervention: Diphenoxylate
Number of subjects: 23
Study 31664751 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% TA combination serum (3% TA, 4% galactomyces ferment filtrate, 2% niacinamide, and 4% alpha arbutin)
Number of subjects: 44
Study 31664751 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% TA combination serum
Number of subjects: 44
Study 31664751 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone
Number of subjects: 44
Study 30011836 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey peptide
Number of subjects: 101
Study 30011836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 26176261 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D schedule (M0,6)
Number of subjects: 240
Study 26176261 — intervention group
Group type: COMPARATOR
Intervention: 3D schedule (M0,1,6)
Number of subjects: 240
Study 24974994 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary Anchorage Devices (TADs)
Number of subjects: 78
Study 24974994 — intervention group
Group type: EXPERIMENTAL
Intervention: Nance button palatal arches
Number of subjects: 78
Study 24974994 — intervention group
Group type: COMPARATOR
Intervention: Headgear
Number of subjects: 78
Study 22257645 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA + COC (oral micronized DHEA 50 mg + 20 µg ethinyl estradiol/0.1 mg levonorgestrel combined oral contraceptive pill daily; n = 43)
Number of subjects: 94
Study 22257645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 37)
Number of subjects: 94
Study 22257645 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA + COC
Number of subjects: 94